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ment of Cell Differentiation, Institute of Molecular Embry-
ology and Genetics, Kumamoto University School of
Medicine, Kumamoto, JapanThe molecular controls for eosinophil development from
multipotential myeloid progenitors, and the mechanisms by
which eosinophil-specific genes are expressed and regulated
during eosinophil terminal differentiation, are incompletely
understood. Recent studies of avian Myb-ets transformed
multipotent haematopoietic progenitors suggest that eosi-
nophil development proceeds via a common neutrophil/
macrophage/eosinophil myeloid precursor that is depen-
dent on PU.1 expression, with the decision to enter the
eosinophil program specified by expression of C/EBPs (C/
EBPa and/or b) in the context of GATA-1 (1). Impaired
eosinophil development occurs in both C/EBPa and C/
EBPe deficient mice (2,3), but PU.1 null mice have not been
studied. To assess the activities of C/EBPs (a, b, e) in
eosinophil differentiation, we have analysed their roles in
regulating the IL-5 receptor a subunit gene (IL-5Ra),
expressed early in eosinophil commitment, and the major
basic protein gene (MBP), expressed during terminal
maturation, in human committed (AML14) promyelocyte
(AML14.eos) and fully differentiated (AML14?3D10)
eosinophil cell lines. Both IL-5Ra (P1) and MBP (P2)
promoters (Fig. 1) possess functional C/EBP sites that bind
C/EBPb and C/EBPe in nuclear extracts of eosinophil-
differentiated AML14?3D10 cells. In contrast, C/EBPa
complexes were detected only in the parental AML14 and
AML14.eos cell lines, but not in AML14?3D10. Both C/
EBPe mRNA and binding activity was identified in all three
cell lines, with AML14?3D1044AML14.eos>AML14?
Human IL-5Ra promoter constructs were transactivated
by C/EBPa, but not by C/EBP b, e-long (32?2 kDa) or e-
short (14?3 kDa) isoforms. However, the MBP promoter
was equally transactivated by C/EBPa or b, less so by e-*First presented at Eosinophil 1999, Lund, Sweden.
0954-6111/00/111135+06 $35?00/0long, and not by C/EBPe-short. Of interest, the C/EBPe-
short isoform inhibited C/EBPa or b transactivation of the
IL-5Ra and MBP promoters. In C/EBPa null mice,
expression of the IL-5Ra gene was reduced approx. five-
fold, but was unaffected by the C/EBPe null mutation.
MBP and eosinophil peroxidase (EPO) mRNAs were
undetectable in C/EBPa null mice, but were only reduced
by approx. 50% in C/EBPe null mice. These findings
support the concept that different C/EBPs (a, b and e) have
distinct regulatory roles during the stages of commitment
versus terminal differentiation. We reported previously that
the MBP promoter also contains a functional GATA-
binding site 7 bp down-stream of its C/EBP site, and is
positively regulated by GATA-1, but negatively regulated
by GATA-2 (4). We have now shown that C/EBPb and
GATA-1 can simultaneously bind their sites in the MBP
promoter, interact physically, and synergize to produce a
five-fold enhancement of activity above that of the
individual factors in a heterologous cell line (5). The
proximity of the GATA-1 and C/EBP sites suggested that
these factors might physically interact, an observation
confirmed by GST-fusion protein pull down experiments
(Fig. 1) (5).
In addition to the regulation of the IL-5Ra subunit gene
by C/EBPa, we had previously characterized the IL-5Ra P1
promoter and identified a 10 bp enhancer element, EOS1
(GTTGCCTAGG, bp7430 to7421), that bound nuclear
factors of human eosinophilic cell lines (AML14, AM-
L14.eos and AML14?3D10), and which was responsible for
>90% of promoter activity in eosinophilic cell lines (6).
Based on DNA sequence analysis, binding activities and
methylation interference data, we have now identified the
EOS1 enhancer (GTTGCCTAGGAGAC, bp 7430 to
7417) as an RFX transcription factor binding site, which
binds RFX proteins as homo- and heterodimers or multi-
mer complexes (Fig. 1). RFX proteins (RFX1-5 and
RFXAP), a multigene family of transcription factors, bind
to x-box elements critical for regulation of all MHC class II
genes including HLA-DR, -DP and -DQ isotypes, the
murine ribosomal rpL30a gene, and enhanced factor C
(EF-C) sites in the promoters of viruses that include
hepatitis B (HBV) and polyoma (Py). The EOS1 enhancer is
essentially identical to the HBV and Py RFX binding sites,
with a two nucleotide difference at the 3’-end. Gel shift
competition analyses showed that formation of the EOS1
complexes with nuclear factors of AML14?3D10 cells
was completely inhibited by the EF-C sites of Py and
HBV, murine rpL30a, and HLA-DRA x-box site, partially
by HLA-DPA, but not by oligonucleotides lacking
palindromic (inverted repeat) sequences characteristic of
viral RFX elements (the HLA-DQA x-box and a mutant of
the IL-5Ra EOS1 site). The same protein-DNA complexes
obtained using nuclear extracts of the AML14?3D10
cell line were obtained using the HLA-DRA x-box site as
a probe instead of EOS1. Since transcription factors# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. Model for the transcriptional regulation of the genes encoding the IL-5 receptor a subunit (IL-5Ra) and granule
major basic protein (MBP) in the eosinophil. The IL-5Ra-P1 and MBP-P2 promoters are shown schematically with dashed
lines and/or question marks indicating potential interactions or binding sites based on studies of these and other myeloid
gene promoters. For the IL-5Ra (P1) promoter, functionally active binding sites for members of the C/EBP and RFX
transcription factor families have been characterized; for the MBP-P2 promoter, functionally active binding sites for the C/
EBP and GATA transcription factor families are indicated. RFX proteins, which bind to an x-box (originally termed the
Eos-1 site) may include RFX-1, -3, -5 and RFX-associated proteins (RFX-AP, RFX-B), and are known to interact with
X2BP-CREB in the regulation of MHC Class II gene expression. In the IL-5Ra promoter, an inducibly active AP-1 binding
site is located immediately upstream of the RFX-binding x-box; AP-1 also interacts with CREB. The IL-5Ra C/EBP site can
be transactivated by C/EBPa and e, but not C/EBPb, whereas C/EBPa, b and e all have activity either independently or are
significantly increased in the context of GATA-1 and PU.1. Activated ras has been reported to phosphorylate and enhance
the activity of C/EBPa for transactivation of the G-CSFR promoter and might function similarly in the eosinophil via the
IL-5-induced lyn kinase pathway. The role for PU.1 in IL-5Ra and MBP regulation may be through AML1 and/or through
interactions with GATA-1 and C/EBPa. For the MBP-P2 promoter, C/EBPa has been shown physically interact and
synergize with GATA-1, whereas GATA-2 competes with GATA-1 and may act as a negative regulator. FOG (friend of
GATA-1) acts as a positive co-factor for GATA-1 regulation of MBP in the eosinophil, in contrast to its role as a negative
regulator in the erythroid lineage.
1136 ABSTRACTSrecognize and interact with DNA in distinct structural
motifs, we modeled binding of the RFX complexes to the
EOS1 element based on their methylation interference
patterns using a cylindrical DNA helical projection. Over a
length of two helical turns, all nuclear protein contacts
indicated by methylation interference mapped to one side of
the DNA helix, suggesting that the RFX protein complex
binds the EOS1 element in the major groove, across the
minor groove, and on only one side of the DNA helix. The
model also reveals a diad symmetry in the binding site,
consistent with the inverted repeat structure of RFX sites in
viral promoters. RFX proteins, which contain bothactivation and repression domains, are expressed in cell-
type and tissue-specific patterns. EOS1 binding complexes
with RFX family members were detected in eosinophil
(AML14, AML14?3D10, HL-60-C15) and other myeloid
(HL-60, U937), lymphoid (B and T) and non-haemato-
poietic (HeLa) cell lines, but not in fibroblasts (NIH3T3) or
COS-7 cells. Expression of RFX1, RFX3, RFX5 and
RFXAP mRNAs was detected in both eosinophilic cell
lines and purified peripheral blood eosinophils from a
patient with the hypereosinophilic syndrome. In bone
marrow-derived CD34þ stem cells, RFX5 and RFXAP
were constitutively expressed, whereas RFX1 and RFX3
FIG. 2 Elicitation and activation of eosinophil–basophil lineage commitment after airway allergen challenge. Eo/B:
eosinophil/basophil; GM-CSF: granulocyte–macrophage colony-stimulating factor; IL-5: interleukin 5; IL-5R’’: high anity
IL-5 receptor ’’ subunit; PPSC: pluripotent stem cell.
ABSTRACTS 1137expression was upregulated in response to IL-3 and/or IL-5
induced eosinophilic differentiation of the CD34þ cells.
Our results indicate that RFX proteins are expressed in
eosinophils, and bind the IL-5Ra EOS1 enhancer as
homodimers, heterodimers or multimer complexes. These
findings indicate that RFX proteins, in addition to C/EBPs,
play a key role in the transcriptional regulation of IL-5Ra
gene expression during both early eosinophil development
and in the mature granulocyte.
Disruption of the PU.1 gene (PU.17/7) severely
impairs development of both lymphoid and myeloid
lineages, resulting in either embryonic lethality by day 16–
18 of gestation (7) or viable mice with no detectable
monocytes, B cells and delayed/reduced neutrophil devel-
opment (8). PU.1 gene disruption causes a severe reduction
but not elimination of myeloid progenitors, which are still
capable of responding to multilineage cytokines, but not to
myeloid-specific cytokines. PU.17/7 progenitors can
undergo only limited differentiation into neutrophils and
monocytes. We have shown that human eosinophils express
PU.1 during IL-5 induced eosinophilic development of
CD34þ progenitors, but nothing was known of the effect of
the PU.1 knockout on eosinophilopoiesis. We have used
RT-PCR to analyse expression of the IL-5Ra gene, and the
lineage-specific EPO and MBP genes in the PU.1 null mice.
Our results show that IL-5Ra, EPO and MBP mRNAs are
not expressed in fetal livers of PU.17/7 embryos. In
contrast, IL-5Ra expression was reduced by approx. three
to four fold in day 9 spleens of viable PU.17/7 mice,
whereas MBP and EPO expression levels were identical to
PU.1þ/þ and PU.1þ/7 mice. Histochemistry showedeosinophils in the bone marrow and spleens of PU.1þ/þ
and PU.1þ/7, but not d16.5 or viable PU.17/7 mice.
These data indicate that eosinophil gene expression is still
detectable in the absence of eosinophil terminal differentia-
tion in both the embryonic lethal (d16.5) and viable PU.1
knockouts, supporting the idea that PU.1 is not essential
for specification of eosinophil precursors, but controls their
proliferation and terminal differentiation by regulating
expression of growth factor receptor and other lineage-
specific genes (Fig. 1).
In summary, these findings support the concept that the
decision ‘to be or not to be (an eosinophil)’, is regulated by
coordinate actions of C/EBPs (a, b and e), GATA proteins
and cofactors [GATA-1, -2, and FOG (5)], RFX factors
and PU.1 on eosinophil target genes (Fig. 2), the majority
of which have not yet been defined.
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Recent studies of the involvement of the bone marrow in
human atopic asthmatic responses to inhaled allergen
confirm what we have found in a canine model of Ascaris
suum-induced bronchial hyperresponsiveness. CD34/45þ
hemopoietic progenitors, increased in numbers in the blood
and marrow of atopic individuals, can be specifically
upregulated following airway allergen challenge eliciting
bronchial hyperresponsiveness and the late-phase response.
All the IL-5 responsive subset of progenitors, making the
Eo-B lineage specifically, is unregulated in the marrow
within 24 h of allergen challenge in dual responder
asthmatics. Using triple colour flow cytometry, it can be
shown that this subpopulation of progenitors in the
marrow is one that bears high anity receptors for IL-5
(IL-5Ra), existing as a subpopulation of early progenitors
bearing CD34/45 (1,2). Thus, the readily mobilizable pool
of autocrine [GM-CSF- and IL-5-producing (3)] Eo-B
progenitors at a very early stage of lineage commitment is
increased after inhalation of allergen, only in those
individuals who develop ongoing inflammatory responses.
The nature of the signalling between the airway and the
bone marrow, which upregulates IL-5Ra on CD34þ
progenitors in the bone marrow in vivo, is not yet known.
We therefore undertook studies to explore the in vitro
regulation of IL-5R expression on hemopoietic progenitors.
Effects of retinoic acid
IL-5 plays a central role in eosinophil and basophil
differentiation, exerting its effects through the IL-5 recep-
tor. Though the a chain of the IL-5R is known to exist as
either a membrane-bound or soluble isoform, little is
currently known concerning regulation of IL-5Ra gene
transcription in the context of commitment of haemopoietic
progenitor cells to the eosinophil and basophil lineages.
Recent studies by Tavernier et al. have indicated that IL-
5 itself can regulate IL-5Ra expression on cord blood-
derived mature eosinophils; recent studies in our laboratoryindicate that the same holds for bone marrow eosinophil
progenitors. Given that all-trans retionic acid (ATRA) is
known to modulate some aspects of haemopoietic differ-
entiation, we examined the effects of ATRA on eosinophil/
basophil differentiation and IL-5Ra expression. In semi-
solid cultures of normal human bone marrow, ATRA
selectivity suppressed eosinophil/basophil colony forming
units, but had no effect on granulocyte–macrophage colony
forming units. Similarly, ATRA inhibited eosinophil/
basophil differentiation of cord blood CD34þ cells, while
neutrophil differentiation proceeded without impediment.
Most importantly, these effects of ATRA or CD34þ cells
were associated with selective, dose dependent inhibition of
membrane-bound IL-5Ra, upregulation of soluble IL-5Ra
transcription, but no change in GM-CSF receptor expres-
sion. These findings indicate that retinoids can differentially
regulate membrane and soluble isoforms of IL-5Ra, and
that these effects have functional consequences in vitro on
eosinophil and basophil differentiation.
Cord blood studies: prediction of
atopy?
The above findings point to an association between allergic
asthma and increased responsiveness of myeloid progenitor
cells to certain haemopoietic growth factors. However, it is
not clear at what age these changes in progenitor cells first
becomes manifest, though increasing evidence suggests that
the allergic phenotype may begin to emerge in very early
life. We therefore compared expression of haemopoietic
cytokine receptors on CD34þ progenitor cells in cord blood
from normal infants (at ‘low risk’ for subsequent atopy),
and infants with at least one atopic first degree relative (‘at
risk’ for subsequent atopy), by flow cytometry. Although
no differences in absolute CD34þ numbers were observed
between the two groups, expression of GM-CSF receptor
on CD34þ cells was significantly reduced in the ‘at risk’
compared to the ‘low risk’ group (P¼0?021), with a
tendency to reduced IL-3 and IL-5 receptor expression in
the ‘at risk’ group (4). While the functional sequelae of
reduced GM-CSF receptor expression on CD34þ cells
remain to be determined, these findings show an association
between genetic risk for atopy and changes in the
expression of haemopoietic cytokine receptors on cord
blood progenitor cells.
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